CEL-SCI Co. (NYSEAMERICAN:CVM) Shares Acquired by Walleye Capital LLC

Walleye Capital LLC lifted its stake in shares of CEL-SCI Co. (NYSEAMERICAN:CVMGet Rating) by 353.3% during the first quarter, Holdings Channel reports. The firm owned 277,278 shares of the company’s stock after buying an additional 216,113 shares during the period. Walleye Capital LLC’s holdings in CEL-SCI were worth $1,090,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in CVM. Virtus ETF Advisers LLC increased its position in CEL-SCI by 108.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 20,792 shares of the company’s stock valued at $148,000 after acquiring an additional 10,832 shares during the period. Northern Trust Corp increased its position in CEL-SCI by 2.1% in the 4th quarter. Northern Trust Corp now owns 371,256 shares of the company’s stock valued at $2,635,000 after acquiring an additional 7,525 shares during the period. Qube Research & Technologies Ltd acquired a new stake in CEL-SCI in the 4th quarter valued at approximately $534,000. M Holdings Securities Inc. acquired a new stake in CEL-SCI in the 1st quarter valued at approximately $109,000. Finally, D.A. Davidson & CO. increased its position in CEL-SCI by 10.1% in the 1st quarter. D.A. Davidson & CO. now owns 429,002 shares of the company’s stock valued at $1,686,000 after acquiring an additional 39,222 shares during the period. 17.75% of the stock is currently owned by institutional investors and hedge funds.

CEL-SCI Stock Performance

Shares of NYSEAMERICAN CVM opened at $4.13 on Monday. The stock has a fifty day moving average price of $4.08 and a two-hundred day moving average price of $3.86. The company has a debt-to-equity ratio of 0.31, a quick ratio of 7.17 and a current ratio of 7.71. The firm has a market cap of $178.94 million, a P/E ratio of -4.86 and a beta of 1.70. CEL-SCI Co. has a 1 year low of $2.49 and a 1 year high of $12.90.

CEL-SCI (NYSEAMERICAN:CVMGet Rating) last issued its quarterly earnings results on Monday, August 15th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). Research analysts forecast that CEL-SCI Co. will post -0.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut CEL-SCI from a “hold” rating to a “sell” rating in a research report on Tuesday, August 23rd.

CEL-SCI Company Profile

(Get Rating)

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Featured Stories

Want to see what other hedge funds are holding CVM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CEL-SCI Co. (NYSEAMERICAN:CVMGet Rating).

Institutional Ownership by Quarter for CEL-SCI (NYSEAMERICAN:CVM)

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.